Daily PubMed evidence board
The impact of timing, dosage, and duration of high-dose methylprednisolone on neurological recovery and complications in acute spinal cord injury: A systematic review and meta-analysis of randomized controlled trials.
This systematic review and meta-analysis pooled randomized controlled trials of high-dose methylprednisolone (MPSS) given for acute traumatic spinal cord…
Signal score47Research triage score
CertaintyLowVerify in full text
PMID42240612Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This systematic review and meta-analysis pooled randomized controlled trials of high-dose methylprednisolone (MPSS) given for acute traumatic spinal cord injury. When MPSS was started within 8 hours of injury, patients had a modest improvement in motor scores compared with placebo. Starting MPSS after 8 hours did not show neurological benefit. Extending the infusion from 24 to 48 hours did not improve recovery and was linked to more serious infections. There was no clear difference in mortality. The findings suggest that if MPSS is used, early (within 8 hours) and time-limited treatment may offer small motor benefits but longer infusions increase complications.
Why it matters
- Addresses whether high-dose methylprednisolone sodium succinate (MPSS) given early after acute traumatic spinal cord injury (SCI) improves motor recovery - a clinically important functional outcome that can affect long-term disability and rehabilitation needs.
- Evaluates the effects of timing (≤8 h versus >8 h) and duration (24 h versus 48 h) of MPSS - operationally relevant for emergency and acute care protocols and guideline decisions.
- Reports harms (serious infectious complications with prolonged infusion) and mortality, which are critical for weighing benefit versus risk when considering corticosteroid use in this vulnerable population.
Primary outcomes
- Neurological recovery assessed by motor score improvement
Effect summary
Abstract-reported pooled findings: MPSS initiated within 8 hours associated with greater motor score improvement (mean difference 4.44 points; 95% CI 0.96-7.93; I2 = 0%). No neurological benefit when MPSS initiated after 8 hours. Extending infusion from 24 to 48 hours did not improve neurological outcomes and was associated with higher rates of serious infectious complications. Mortality did not differ significantly between MPSS and control groups.
Benefit-cost lens
| Quick take | Abstract-level evidence suggests a modest motor-score benefit when high-dose MPSS is started within 8 hours of injury, no benefit if started later, and increased serious infections with infusions extended to 48 hours. Full-text details and local costing, baseline risks, and implementation feasibility are needed before any policy or practice change. |
|---|---|
| BCR anchor | 1 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Assessment based solely on PubMed metadata and abstract. Assumes pooled RCT data reported in abstract reflect primary analyses; does not account for trial heterogeneity, subgroup detail, or secondary analyses only accessible in full text. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | Cochrane RoB 2 (as reported in abstract) / rapid-abstract-screen judgement |
|---|---|
| Verdict | Uncertain; moderate-to-high risk of residual bias possible |
| Notes | The abstract states RoB 2 was used and GRADE applied, but only abstract-level results are available here. Without full-text access, trial-level risk-of-bias domains (randomization, deviations, missing data, outcome measurement, selective reporting), heterogeneity sources, and sensitivity analyses cannot be verified. Results should be interpreted cautiously pending full-text appraisal. |
Harms, equity, conflicts & implementation
| Implementation | Full-text review of included trials for dosing regimens, eligibility, and monitoring requirements; local assessment of ability to administer MPSS within 8 hours (prehospital and emergency logistics); protocols for limiting infusion duration to 24 hours; surveillance for infectious complications; cost and staffing implications; and stakeholder (neurosurgery, trauma, critical care, rehab) alignment. |
|---|---|
| Equity impact | Unclear from abstract. Potential equity concerns if time-to-presentation or access to rapid acute care varies across populations, which would affect who could receive early MPSS and who might face increased infection risk with prolonged infusion. |
| Harms | Abstract indicates higher rates of serious infectious complications with infusion extended to 48 hours; gastrointestinal bleeding, hypoglycemia, and mortality were assessed but mortality did not differ. Full-text data needed for absolute harm rates and other adverse-event details. |
| Replication | Unknown from abstract-level triage; replication and confirmatory analyses require examination of included trials and subsequent studies. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.